{"id":"dapaglifozin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Viral upper respiratory tract infection","drugRate":"12.5%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":24,"totalAffected":3,"trialsReporting":1},{"effect":"Tachycardia","drugRate":"8.3%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":24,"totalAffected":2,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"8.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":2,"trialsReporting":1},{"effect":"Nausea","drugRate":"8.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":2,"trialsReporting":1},{"effect":"Hyperhidrosis","drugRate":"8.3%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":24,"totalAffected":2,"trialsReporting":1},{"effect":"Headache","drugRate":"4.2%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Tachycardia paroxysmal","drugRate":"4.2%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Tinnitus","drugRate":"4.2%","organSystem":"Ear and labyrinth disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Dyspepsia","drugRate":"4.2%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Gastroenteritis","drugRate":"4.2%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Genital infection fungal","drugRate":"4.2%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Oral herpes","drugRate":"4.2%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Otitis media","drugRate":"4.2%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Arthropod sting","drugRate":"4.2%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Decreased appetite","drugRate":"4.2%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Food craving","drugRate":"4.2%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Hypoglycaemia","drugRate":"4.2%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Back pain","drugRate":"4.2%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Dysmenorrhoea","drugRate":"4.2%","organSystem":"Reproductive system and breast disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Pruritus genital","drugRate":"4.2%","organSystem":"Reproductive system and breast disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Rash pruritic","drugRate":"4.2%","organSystem":"Skin and subcutaneous tissue disorders","placeboRate":"","totalAtRisk":24,"totalAffected":1,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Constipation","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Vomiting","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Palpitations","drugRate":"0.0%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Ear discomfort","drugRate":"0.0%","organSystem":"Ear and labyrinth disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Abdominal distension","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Abdominal pain","drugRate":"0.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site erythema","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Bronchitis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Procedural nausea","drugRate":"0.0%","organSystem":"Injury, poisoning and procedural complications","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"0.0%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Dizziness","drugRate":"0.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Balanoposthitis","drugRate":"0.0%","organSystem":"Reproductive system and breast disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1},{"effect":"Rhinorrhoea","drugRate":"0.0%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":24,"totalAffected":0,"trialsReporting":1}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_sources":{"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T10:55:15.267087+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1"},"_scrapedAt":"2026-03-28T01:08:37.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T10:55:22.448549+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Chronic heart failure","diseaseId":"chronic-heart-failure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic kidney disease","diseaseId":"chronic-kidney-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diabetes mellitus type 1","diseaseId":"diabetes-mellitus-type-1","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Diabetes mellitus type 2","diseaseId":"diabetes-mellitus-type-2","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07488689","phase":"PHASE3","title":"Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-07","conditions":"Septic Shock","enrollment":568},{"nctId":"NCT07491718","phase":"NA","title":"Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-08-08","conditions":"Takotsubo Cardiomyopathy","enrollment":100},{"nctId":"NCT06578520","phase":"PHASE4","title":"Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure","status":"RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2024-07-30","conditions":"Heart Failure","enrollment":31},{"nctId":"NCT04234867","phase":"PHASE1","title":"Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D)","status":"TERMINATED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2022-05-18","conditions":"Type 1 Diabetes, Diabetic Ketoacidosis","enrollment":2},{"nctId":"NCT06711185","phase":"PHASE3","title":"Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy","status":"RECRUITING","sponsor":"University of Campinas, Brazil","startDate":"2024-01-30","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT02987738","phase":"PHASE1","title":"Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2017-02-09","conditions":"Type1diabetes","enrollment":30},{"nctId":"NCT06572215","phase":"","title":"DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2023-12-14","conditions":"Chronic Kidney Diseases","enrollment":44},{"nctId":"NCT06373523","phase":"EARLY_PHASE1","title":"MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-09-01","conditions":"Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease","enrollment":60},{"nctId":"NCT06326528","phase":"","title":"SGLT2 Inhibitors and Perioperative Period","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-05-01","conditions":"Perioperative Complication","enrollment":100},{"nctId":"NCT05713851","phase":"PHASE2, PHASE3","title":"Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2023-01-01","conditions":"AKI - Acute Kidney Injury, Biomarkers, Transition to CKD","enrollment":100},{"nctId":"NCT04707352","phase":"PHASE3","title":"Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2021-02-08","conditions":"Heart Failure","enrollment":162},{"nctId":"NCT05934071","phase":"","title":"Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-10-10","conditions":"Heart Failure, Ventricular Remodeling, Ventricular Dysfunction","enrollment":160},{"nctId":"NCT04697485","phase":"PHASE4","title":"Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2021-01-08","conditions":"HF - Heart Failure, Diabetes Mellitus","enrollment":""},{"nctId":"NCT05225077","phase":"PHASE4","title":"Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients","status":"UNKNOWN","sponsor":"Dong-A University","startDate":"2022-01-01","conditions":"Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention","enrollment":600},{"nctId":"NCT05032001","phase":"NA","title":"ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT","status":"UNKNOWN","sponsor":"Metabolic Research Unit","startDate":"2021-08-01","conditions":"Abdominal Obesity, Type 2 Diabetes","enrollment":30},{"nctId":"NCT05014594","phase":"PHASE2","title":"Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2021-09-03","conditions":"Cirrhosis, Ascites Hepatic","enrollment":44},{"nctId":"NCT04806633","phase":"EARLY_PHASE1","title":"Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention","status":"UNKNOWN","sponsor":"G.Gennimatas General Hospital","startDate":"2021-04-01","conditions":"Left Cardiac Catheterization, Percutaneous Coronary Intervention, Acute Kidney Injury","enrollment":1722},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT04242758","phase":"PHASE4","title":"Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy","status":"UNKNOWN","sponsor":"University of Pisa","startDate":"2019-06-04","conditions":"Renal Function Disorder, Glucose Metabolism Disorders","enrollment":30},{"nctId":"NCT03444584","phase":"PHASE2","title":"Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-05-08","conditions":"Type 2 Diabetes Mellitus","enrollment":49},{"nctId":"NCT02966626","phase":"","title":"A Real World Experience of Dapagliflozin in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Malaya","startDate":"2017-01","conditions":"Type2 Diabetes","enrollment":223},{"nctId":"NCT02325206","phase":"PHASE1","title":"Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2014-12","conditions":"Type 1 Diabetes","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":46,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"structuredTrialResults":[{"hr":"-143.09","nctId":"NCT03444584","phase":"PHASE2","pValue":"<0.0001","ciLower":"-198.20","ciUpper":"-87.98","endpoint":"Change From Baseline to Day 28 in Plasma Glucose Area Under the Concentration Time-curve From Time 0 to 4 Hours (AUC0-4hrs) as Measured by Mixed-meal Tolerance Test (MMTT)","enrollment":49}],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"Dapaglifozin","genericName":"Dapaglifozin","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":1,"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T10:55:22.448549+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}